Highlights

Fast Facts

• A heritage more than 130 years strong: company founded on May 10, 1876
• Headquarters located in Indianapolis, Indiana, U.S.A
  
• Approximately 40,217 employees* worldwide
• Approximately 7,946 employees engaged in research and development
• Clinical research conducted in more than 50 countries
• Research and development facilities located in 7 countries
• Manufacturing plants located in 13 countries
• Products marketed in 143 countries

Introduced:

• Byetta®, a first in a new class of medicines known as incretin mimetics to treat type 2 diabetes
• Cymbalta®, for major depressive disorder and diabetic peripheral neuropathic pain
• Alimta®, the first and only chemotherapy regimen approved by the FDA to treat patients with malignant pleural mesothelioma who are not candidates for surgery
• Symbyax®, for bipolar depression
• Cialis®, a distinctive new treatment for erectile dysfunction from the Lilly ICOS joint venture
• Strattera®, the first FDA-approved nonstimulant, noncontrolled medication for the treatment of attention-deficit hyperactivity disorder in children, adolescents, and adults
• Forteo®, first-in-class medicine for osteoporosis patients that stimulates new bone formation
• Xigris®, the first treatment approved for adult severe-sepsis patients at a high risk of death
• Evista®, the first in a new class of drugs for the prevention and treatment of postmenopausal osteoporosis
• Zyprexa®, breakthrough product for schizophrenia and acute mania associated with bipolar disorder
• Humalog®, a fast-acting insulin product
• Gemzar®, for pancreatic and non-small-cell lung cancer, one of the world's best-selling oncology agents
• Humatrope®, therapy for growth hormone deficiency
• Prozac®, which revolutionized the treatment of depression
• Humulin®, human insulin, the first human-health-care product created by biotechnology
• Ceclor®, which became the world's top-selling oral antibiotic
• Iletin®, the first commercially available insulin product, in 1923

back to the top